

Lecithin as a putative biodegradable blocker of SARS-CoV-2

Muhammad Nawaz Qaisrani^{a,b,1}, Jawad ur Rehman^{c,2}, Roman Belousov^a, Elham Moharramzadeh Goliaei^a, Ivan Giroto^a, Ricardo Franklin^a, Oriol Güell^{d,*}, Ali Hassanali^{a,*}, and Édgar Roldán^{a,*}

^aICTP - The Abdus Salam International Centre for Theoretical Physics, Strada Costiera 11, 34151 Trieste, Italy; ^bSISSA - International School for Advanced Studies, Via Bonomea 265, 34136 Trieste, Italy; ^cUniversity di Trieste; ^dComercial Douma S.L., Carrer de València 5, 08015 Barcelona, Spain

This manuscript was compiled on July 20, 2020

Understanding the physical and chemical properties of viral infection at molecular scales is a major challenge of the scientific community in the fight against the Coronavirus (COVID-19) pandemic. We employ all-atoms molecular dynamics simulations to study the interaction between the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and the surfactant lecithin, in water solutions. Our microsecond simulations reveal a preferential binding of lecithin to the receptor-binding motif (RBM) of SARS-CoV-2. Furthermore, we find that the lecithin-RBM binding events are mainly dominated by the hydrophobic interactions, which are accompanied by dewetting of water molecules near the RBM. These proof-of-concept simulations provide a demonstration of the use of biodegradable phospholipids as blockers of binding of SARS-CoV-2 with the human Angiotensin Converting Enzyme 2 (ACE2) receptor.

SARS-CoV-2 | Coronavirus | COVID-19 | Spike protein | Lecithin | Molecular dynamics

Over the last century, humanity has been threatened by several deadly viruses including Spanish flu, SARS Coronavirus (SARS-CoV), Influenza A (H1N1, H5N1), Ebola, Middle East Respiratory Syndrome (MERS-CoV), Zika, and recently Coronavirus disease 2019 (COVID-19 or SARS-CoV-2) (1–3). To date, the total number of COVID-19 positive cases are in the order of millions according to the World Health Organization report (4). Due its rapid transmission and high rate of mortality, scientists from different disciplines are putting together efforts in the global endeavour of tackling the Coronavirus pandemic.

The molecular structure of SARS-CoV-2 is formed by lipid membrane, nucleocapsid proteins, and spike proteins, which together shield the RNA genome of the virus. It has been shown that spike proteins play a key role in virus fusion and entry (5), hence they have become one of the key targets for drug design and vaccine development (6–9). SARS-CoV-2 spike protein is formed by two subunits, denoted by S1 and S2. The S1 subunit binds through its receptor bonding motif (RBM) to the ACE2 (Angiotensin-converting enzyme 2) on the cell membrane surface of lung. On the other hand, the S2 subunit mediates the fusion of the virus with the human host cells (10). In addition, it is believed that variations in S and ACE2 sequences can not allow for viral infection across species (11, 12). Recent work has shown that SARS-CoV-2 spike protein binds to ACE2 human receptor with approximately 15nM affinity which is higher than the affinity of SARS-CoV S to ACE2 (13) and it leads to increase virulence of COVID-19 (11, 14, 15). The protein and ACE2 can interact via hydrogen bonding, hydrophobic and electrostatic interactions (16–18). There have been numerous attempts to design or re-purpose drugs that would inhibit the binding of the spike protein to ACE2 (19–22). However, the

underlying physical principles that drive these interactions are yet poorly understood. To explore novel and potent drugs, a fundamental understanding of the interplay of molecular forces involving the spike protein, potential inhibitors and of course the surrounding aqueous medium, is critical.

Herein we adopt an unorthodox yet holistic approach and focus our efforts on proof-of-concept simulations that demonstrate that the binding sites of SARS-CoV-2 with ACE2 can be blocked by "soapy" molecules. Specifically, we show with microsecond timescale atomistic molecular dynamics simulations, that a bio-degradable, amphiphilic molecule, phosphatidylcholine (POPC) which forms the phospholipid constituent of a commercially well-known product called lecithin. We show that his molecule appears to form strong and stable aggregates driven by hydrophobic interactions and water dewetting, in close proximity to the RBM zone and may thus hinder interactions with the ACE2 receptor.

The role of water and hydrophobicity in viral inhibition is not unprecedented. Specifically, recent works have reported the efficiency of CB6 antibody and EK1C4 inhibitor in building hydrophobic interactions with SARS-CoV-2 (23, 24). On the other hand, B38 antibody binds to SARS-CoV-2 RBM via hydrophilic interactions, proposing that water molecules play an important role in the interaction (25). Interestingly, the role of hydrophobicity and hydrogen bond networks have also been implicated in the interactions of both Zika and HIV viral membranes constituted by POPC bilayers (26, 27).

In the following we study, using molecular dynamics simulations, the interaction between SARS-CoV-2 receptor binding domain (RBD) and a biodegradable molecule that can be extracted from both vegetable oils (e.g. soybean) and animal tissues (e.g. eggs) (28, 29). More precisely, we focus on the phosphatidylcholine called 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine $C_{42}H_{82}NO_8P$ (POPC), which we will refer to throughout the paper as lecithin. We show that this molecule binds preferentially the receptor binding motif (RBM) of the spike protein driven by the formation of non-polar contacts. Furthermore, lecithin significantly alters the secondary structure of the spike protein to an extent that is strongly modulated by the concentration of the phospholipid. Notably, all these processes are accompanied by a significant change in the water fluctuations at the vicinity of the RBM interface. These results

MNQ and EG performed simulations. MNQ, JR, RB, and RF analyzed data. MNQ, JR, and OG discussed physico-chemistry aspects. IG provided computing support. OG, AH, and ER proposed and established the project, and AH and ER directed it. All authors discussed and wrote the manuscript.

The authors declare no competing interests.

*To whom correspondence should be addressed. E-mails: oriol@comercialdouma.com (OG), ahassana@ictp.it (AH), edgar@ictp.it (ER).




Fig. 1. **A)** Illustration of the X-ray crystal structure of SARS-CoV2 spike protein receptor binding domain (RBD, multicolor) and human ACE2 receptor (green) (31). **B)** Zoomed view of SARS-CoV-2 RBD, where different colours indicate different zones selected to interrogate the RBD-lecithin interactions at different solvent exposures. The red highlighted part is the receptor-binding motif (RBM) of the protein. **C)** Amino acid sequence corresponding to the crystal structure of SARS-CoV-2 RBD with the different zones highlighted in different colors. The red dots below few residues indicate those amino acids involved in the interaction with the human ACE2 receptor.

75 open up the possibility of the use of surfactants in drug design.

76 1. System Setup

77 In this section we introduce and discuss physicochemical properties of the system in which we focus our study, the SARS-
78 CoV-2 receptor binding domain (RBD) and lecithin in water.
79

80 **A. SARS-CoV-2 receptor binding domain.** Figure 1A illustrates the crystal structure of SARS-CoV2 RBD (multi-colour)
81 bound to the human ACE2 receptor (green)(30). A zoomed-in
82 view of the RBD crystal structure is displayed in Fig. 1B
83 with the RBM highlighted in red. The residue sequence and
84 its cryo-EM structure of S glycoprotein's RBD were adopted
85 from Ref. (30). In order to dissect, and better interrogate
86 the protein-lecithin interactions we divided the RBD into non-
87 overlapping zones. Fig. 1B shows the five different regions
88 in different colors in the protein structure labelled as Zone 1
89 (orange), Zone 2 (cyan), Zone 3 (yellow), the receptor-binding
90 motif RBM (red) and Zone 4 (purple). The RBM is the
91 largest domain and carries the residue sequence from Asn439
92 to Gln505 which has been shown to interact with human ACE2
93 receptor (31).
94

95 **B. Lecithin.** While it is well known that surfactant-protein
96 interactions play an important role in biological contexts, the
97 underlying physical driving forces that drive these processes
98 remain poorly understood(32). Here, we focus our efforts

99 on the phospholipid POPC (1-palmitoyl-2-oleoyl-sn-glycero-
100 3-phosphocholine), which we will refer throughout the paper
101 as lecithin, a biodegradable, essential phospholipid for the
102 human body. Lecithins are ubiquitous in mammalian organs,
103 they help to build the largest choline reservoir and they are
104 found in the bile (33), and more importantly in the alveolar
105 surface in the lung (34, 35). Lecithin's chemical structure is
106 shown in Fig. 2A. It is a surfactant consisting of a glycerol
107 backbone sterified in positions 1 and 2 with a palmitic and an
108 oleic acid, both constituting the hydrophobic non-polar tail
109 able to interact with non-polar residues. The position 3 of the
110 backbone is linked to a phosphate group which is bonded to a
111 choline group, forming the hydrophilic polar head of lecithin.

112 Lecithin is amphiphilic and therefore has potential to inter-
113 act with the spike protein using a combination of both
114 polar and non-polar interactions. In fact, the hydrophilic-
115 lipophilic balance (HLB) of lecithin ranges from values to
116 4 ± 1 to 9.7 ± 1 (36). Thus, it lies in the range of w/o (water in
117 oil) emulsifying agents and also of wetting spreading agents.
118 This is a crucial property that makes lecithin POPC an ideal
119 candidate to act as a molecule targeting SARS-CoV-2, since
120 one will need both polar and non-polar parts, the former re-
121 lated to the polar amino acids of proteins, whereas the latter
122 involves the protein hydrophobic regions. Moreover, at large
123 concentrations lecithin can aggregate into micelles (37). As
124 we will see later, the aggregation of lecithin in close proximity
125 to the spike protein might serve as a blocking mechanism for
126 ACE2 binding with SARS-CoV-2.

127 2. Results

128 We performed all-atoms molecular dynamics (MD) simulations
129 using the open-source software GROMACS 2020 (38, 39). All
130 our simulations were conducted in the canonical NVT en-
131 semble at a temperature of $T = 298.5\text{K}$, within a cubic simu-
132 lation box with side-length 10nm and periodic boundary
133 conditions containing 30634 water molecules. A time step of
134 2fs was used for all simulations. To simulate the interaction
135 between SARS-CoV-2 RBM, lecithin and water, we employed
136 the OPLS-AA (40) force field together with the SPC/E model
137 of water (41). After an initial equilibration of the RBD crystal
138 structure for ~ 2 ns, we ran production simulations of $1.2 \mu\text{s}$
139 long. In order to assess the role of increasing concentration
140 of lecithin, four different values of lecithin concentration, cor-
141 responding to $N_L = 0$ (RBD + water), 5 (RBD + lecithin +
142 water), 10 and 15 lecithin molecules in the simulation box,
143 were used. For each simulation containing lecithin, three inde-
144 pendent initial conditions were launched. See computational
145 Methods A for further details.

146 In order to build our intuition on the nature of the inter-
147 actions between lecithin and the spike protein, we begin by
148 inspecting representative snapshots of our molecular dynam-
149 ics simulations (see Supplementary Movies ??). Figure 2B
150 shows the initial condition in a zoomed-in snapshot of the
151 simulation box for $N_L = 10$ lecithin molecules. Over time,
152 lecithin molecules –initially at random positions in the simu-
153 lation box– diffuse into the hydration shell of the protein
154 and appear to have an affinity for certain regions of the spike
155 protein. More specifically, we observe that lecithin molecules
156 adhere to the RBM zone as well as Zone 2. Figures 2C-D
157 are representative snapshots taken after $1 \mu\text{s}$ simulation time
158 for lecithin concentrations corresponding to $N_L = 10$ and




Fig. 2. **A)** Molecular (top) and chemical (bottom) structure of a lecithin POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) molecule. The bottom figure highlights its polar (hydrophilic) and non-polar (hydrophobic) chemical groups. **B)** Snapshot of the one initial condition of the simulation setup at, showing the receptor binding domain of SARS-CoV-2 spike protein in the lecithin solution, with water molecules depicted as transparent gray spheres. **C-D)** Snapshots taken at times larger than $1 \mu s$ for two different values of the lecithin concentrations corresponding to 10 (C) and 15 (D) number of lecithin molecules in the simulation box. For the sake of better visualization, we do not include the water molecules in panels C and D.

159 $N_L = 15$ illustrating this phenomenon.

160 There are several interesting features that one can observe
 161 in these binding events of involving lecithin. Firstly, lecithin
 162 molecules stick around the RBM and Zone 2 either as single
 163 molecules (Fig. 2C) or in the form of clusters (Fig. 2D). Fur-
 164 thermore, the simulations also reveal that lecithin docks to the
 165 viral protein mostly involving the hydrophobic non-polar tail.
 166 Overall, Figure 2D shows the aggregation of lecithin into two
 167 clusters, one near the RBM and another in close proximity to
 168 Zone 2 (cf. Fig. 1B). Note that Zone 2 is exposed to the
 169 solvent in our simulations, but is bound to the core of the spike
 170 protein in the virus, hence it may be accessible to lecithin
 171 when the spike-protein trimer opens due to fluctuations or
 172 interactions with other proteins.

173 In the following, we provide a quantitative analysis of our
 174 simulations, by first looking in Sec. 2A at the global structural
 175 behavior of the SARS-CoV-2 RBD monitoring its radius of
 176 gyration. To investigate the protein-lecithin interactions at
 177 the atomic level, we present in Sec. 2B a detailed contact
 178 map analysis disentangling the interactions involving the polar
 179 and non-polar groups of the lecithin molecules with different
 180 SARS-CoV-2 RBD residues. As we will see later, in Sec. 2C,
 181 the interaction of the hydrophobic parts of lecithin with the
 182 spike protein, reveals the crucial role of water fluctuations
 183 during the interaction of the spike protein with its aqueous
 184 environment.

185 **A. Radius of Gyration.** To monitor the change in the struc-
 186 ture of SARS-CoV-2 RBD resulting from its interaction
 187 with lecithin, we measure the radius of gyration (RG) of
 188 the RBD as a function of time. In particular, we evaluate
 189 $RG(t) = (\sum_i m_i ||\mathbf{r}_i(t)||^2 / \sum_i m_i)^{1/2}$, where m_i and $\mathbf{r}_i(t)$ is
 190 the mass and position of each i -th atom respectively, with
 191 respect to the center of mass of the molecule to which it be-
 192 longs to. We consider here two different RGs of interest: (i)
 193 RG of all the heavy atoms in the SARS-CoV-2 RBD; and (ii)
 194 RG of all the heavy atoms in the RBM. The distribution of
 195 the RGs (Figs. 3A-B) show that lecithin significantly changes
 196 the structure of the RBD and in particular, the RBM part
 197 and that this effect is highly sensitive to the concentration of
 198 lecithin in water.

199 **B. Atlas of Lecithin-Spike Protein Molecular Interactions.** In
 200 this section, we investigate the interatomic contacts that form




Fig. 3. Distribution of radius of gyration of SARS-CoV-2 spike protein receptor binding domain RBD (A) and of its receptor binding motif RBM (B) for different concentrations of lecithin (see legend, where N_L denotes the number of lecithin molecules). The data is obtained from a single $1 \mu s$ molecular-dynamics simulation for each lecithin concentration value.

201 between lecithin and spike protein. To this aim, we plot in
 202 Fig. 4 contact maps between all the heavy atoms * in the
 203 protein residues of SARS-CoV-2 RBD and lecithin molecules
 204 for the lecithin concentration value $N_L = 15$. We focus this
 205 analysis on two quantities, namely the average interatomic
 206 distance (Fig. 4A-B) and the average interaction time (Fig. 4C-
 207 D) between lecithin and the different viral protein zones (see
 208 Fig. 1). Figs. 4A and C, show the interaction distances and
 209 times that lecithin forms with the entire RBD. Consistent with
 210 Fig. 2, we observe that there are some hot-spot regions where
 211 lecithin prefers to bind, in particular, Zone2 and RBM. Within
 212 these regions, the interatomic distances between lecithin and
 213 the viral protein are less than one nanometer. Since the
 214 RBM zone is the one that interacts with ACE2 we focus on
 215 examining its contacts with lecithin in Fig. 4B. Specifically,
 216 lecithin appears to form close contacts with amino acids 473-
 217 490, which contain ACE2-interacting residues (cf. Fig. 1C).

218 The bottom panels of Fig. 4 show the corresponding maps
 219 built on the interaction times associated with lecithin and
 220 the protein. In order to classify the times of interaction, a
 221 threshold distance of 1nm corresponding to the typical range
 222 of van-der-Waals forces, was used. We find that the average in-
 223 teraction time between lecithin and the RBD is on the order of
 224 hundreds of nanoseconds. As expected, the core of the protein
 225 (Zone 3) is characterized by the weakest binding. We observe

* All our contact maps are evaluated taking into account the positions of all except the hydrogen atoms, i.e. only the heavy atoms.




Fig. 4. **A)** Contact map between different zones of SARS-CoV-2 receptor binding domain (RBD) and lecithin molecules. The positions of all the heavy atoms are used to define contacts as function of distances up to 1nm scale (see colorbar). **B)** Zoomed-in view of (A) showing the interaction distance contact map between the RBM zone and lecithin molecules. **C-D)** Total interaction time (relative to the simulation time, in %) of lecithin molecules with SARS-CoV-2 RBD (**C**) and with its RBM (**D**). The latter is given by the time spent at distances below 1nm.




Fig. 5. Average contact maps between different zones of SARS-CoV-2 receptor binding domain (RBD) and lecithin polar (**A**) and non polar (**A**) groups, see text for more details.

226 similar trends in our simulations at lower concentrations of
 227 lecithin, i.e for $N_L = 5$ and $N_L = 10$ lecithin molecules (see
 228 the SI).

229 To gain further insights into the physical driving force
 230 between the molecular interactions, we investigate the average
 231 contact maps of polar and non polar groups of lecithin
 232 molecules with the RBM residues. To this aim, we compute
 233 the average interatomic distance between the RBM atoms and
 234 two different parts of lecithin molecules: (i) the hydrophobic
 235 alkyl chain (see Fig. 5B); and (ii) the hydrophilic charged
 236 group (see Fig. 5C). Notably, the interatomic distance between
 237 all the subdomains of the RBM and the hydrophobic tail of
 238 lecithin molecules is significantly smaller than the distance to
 239 the hydrophilic head. Therefore the lecithin-RBM contacts
 240 are mainly dominated by the hydrophobic interactions and in
 241 fact, this is enhanced under higher concentrations of lecithin.

242 **C. Water dewetting near the receptor-binding motif.** It is well
 243 known that water plays an instrumental role in tuning the
 244 structural and dynamical properties of biological systems (42).
 245 In the context of our work, there have been numerous studies
 246 showing the important role of water dewetting in facilitating
 247 the hydrophobic interactions proteins (43, 44). The preceding
 248 analysis, shows that hydrophobic interactions between the
 249 non-polar groups of lecithin form close contacts with the RBM.
 250 In order to explore the importance of the reorganization of
 251 the solvent environment during the RBM-lecithin binding, we
 252 show in Fig. 6 the radial distribution of water molecules $g(r)$
 253 of sixteen residues in the RBM, which have been implicated
 254 in the docking mechanism of SARS-CoV-2 and ACE2 (45).

255 In order to probe the dewetting of the RBM's surface
 256 induced by the presence of lecithin in the water solution, we
 257 illustrate the RDFs of two amino acids, Ala475 and Phe486

258 which correspond to alanine and phenylalanine both of which
 259 are hydrophobic residues (dashed curves correspond to RBM
 260 in the absence of lecithin and solid with $N_L = 15$). Strikingly,
 261 we observe that there is a drastic depletion in the water density
 262 over a length scale of 1nm near both these amino acids in the
 263 presence of lecithin. This effect can be clearly seen in Fig. 7
 264 which illustrates the hydration shell around Phe486 in the
 265 absence and in the presence of a cluster of lecithin.

266 The RBM zone interacting with ACE2 is actually made up
 267 of sixteen amino acids. In order to establish how the solvent
 268 reorganizes across the entire RBM-ACE2 binding region, we
 269 determined the hydration shell outer radius r_o , defined as
 270 the position of the Gibbs dividing interface, for these sixteen
 271 aminoacids with and without lecithin in solution. Notably, r_o
 272 increases upon addition of lecithin for all these residues. The
 273 inset of Fig. 6 shows the relative change of the sixteen amino
 274 acids r_o in the RBM-ACE2 junction. All sixteen undergo a
 275 depletion of water density to different extents, with residues
 276 Ala475 and Phe486 displaying a striking increase of more than
 277 100%.

3. Discussion

278
 279 In this work we have studied with molecular dynamics simula-
 280 tions the interaction between SARS-CoV-2 receptor binding
 281 domain (RBD) and lecithin molecules in water. Our main
 282 results are summarized as follows: (i) lecithin induces a con-
 283 formational change in the RBD and its receptor binding motif
 284 which is revealed by an increase of the radius of gyration with
 285 the lecithin concentration; (ii) lecithin molecules bind mostly
 286 by docking their hydrophobic tails into the viral protein sur-
 287 face. This hydrophobic interaction occurs at distances that are




Fig. 6. Radial distribution function $g(r)$ of water molecules plotted as a function of distance r from the 16 amino acids of the RBM domain which are involved in binding with ACE2 (the residues highlighted with red dots in panel C) of Fig. 1). The analysis is done for 1.2 μ s long trajectory of system with $N_L = 15$ (solid lines) and $N_L = 0$ (dashed lines) lecithin in water solution respectively. The horizontal line illustrates the increase of the hydration shell's outer radius r_o , which is delimited by the position of the Gibbs dividing interface $g(r_o) = 0.5$. We reproduce $g(r)$ only for the amino acids Ala475 and Phe486, near which the hydration shell is depleted the most due to the hydrophobic interactions with the lecithin molecules. The inset reports the percentage change of r_o for all the sixteen residues that we examined. Ala475 and Phe486 are singled out by the same colors as in the main plot. Note that as reference positions of the H_2O groups and amino acids we chose the oxygen and the alpha carbon atoms, respectively.




Fig. 7. A) Zoomed Snapshot taken from the simulation of the system where protein is in pure water and B) when protein is in lecithin solution. The hydration water within 5 Å from the Phe486 residue (in green) which is the part of RBM (transparent red coils) is shown in both cases. In the vicinity of lecithin cluster (shown by glassy balls and sticks) when it formed near the RBM residues over hundreds of nanoseconds simulation time, the hydration shell is significantly depleted due to the hydrophobic interaction of lecithin molecules hence dewetting of the protein residues.

multi-GPUs version of the open-source package GROMACS 2020 (38, 39). Adopting an high-throughput approach we ran multiple simulations in parallel on several compute nodes of the recently installed Marconi100 at CINECA, a world-class European Tier-0 system for high-performance computing (HPC). Each simulation was performed with the single node version (threadMPI+CUDA) of the software, highly optimized to fully exploit the compute capability available on the accelerated cluster. Indeed, a single compute node of Marconi100 is equipped with 2x IBM Power9 CPUs and 4x V100 NVIDIA GPUs, delivering high-bandwidth data streaming between the CPUs and GPUs via NVLink 2.0. In particular, three of the GPUs on the Marconi100's nodes were used for computing the particle-particle force interaction, while having one GPU dedicated to compute the PME long-range electrostatic calculations, in a configuration capable to deliver a performance up to about 190ns/day of MD simulation, using a single compute node of the accelerated system for HPC. In all these simulations, we used the OPLS-AA(40) force field together with the *SPC/E* water model(). The dimensions of the simulation box were 10 nm in the cubic geometry, containing 30634 water molecules. The simulations with concentrated lecithin solution were performed using number of lecithin molecules $N_L = 5$, $N_L = 10$, $N_L = 15$ respectively. Furthermore, to assess the sensitivity of different choices of the POPC molecules positions at $t = 0$ in the simulation box, three different initial conditions were generated for each concentration of the lecithin solution. A cut-off radius of 1.2 nm was used to create a non-bonded pair list. For the short-range non-bonded interactions a cut-off length at 1.1 nm was chosen for a shifted Lennard-Jones potential while the long-range electrostatic interactions were taken into account via Particle Mesh Ewald-Switch(48) (PME-switch) method with a Coulomb switching cut-off at 1.2 nm. A long-range dispersion correction was applied for truncating the van-der-Waals interactions. All bonds were constrained using the LINCS algorithm(49). A time step of 2 fs was used for the Verlet integrator. All simulations were conducted in the canonical ensemble (NVT) at 298.5 K using the velocity-rescale thermostat(50) with a time-constant of 0.1 ps. The production runs for all simulations after initial equilibration were extended up to 1.2 μ s.

smaller than 1nm and on timescales on the order of ~ 100 ns. (iii) The lecithin-RBD hydrophobic binding is accompanied by a dewetting of water molecules in the receptor binding motif. Taken all together, these results suggest the possible role of soapy-like molecules as potential biodegradable blockers of the interaction between SARS-CoV-2 RBD and ACE2 receptor.

As stressed earlier, the observations we make here of lecithin SARS-CoV-2 interactions serves as a proof of concept for the role of surfactants in drug design. For example, phospholipids have been employed earlier to treat SARS-CoV (46). Moreover, lecithin has been used as drug component to dose lactoferrin for SARS-CoV-2 prevention (47). Finally, a key point of our study is that the presented results could be extended to a mixture of amphiphilic phospholipids, not only limited to lecithin.

While we cannot make any quantitative predictions on the binding affinities or kinetics from our current simulations, the insights we have uncovered involving the important role of hydrophobic interactions and water fluctuations, is an important result. In a time where a microscopic understanding of this global pandemic remains unknown, we believe that these simulations make important first steps to fill this gap.

ACKNOWLEDGMENTS

We thank the HPC agreement between the ICTP and CINECA for making available the computer power needed for this research.

Supporting Information Appendix (SI).

A. Computational Methods. To investigate the structural and dynamical behaviour of SARS-COV2 RBD protein in clean water and concentrated POPC solutions, all atoms molecular dynamics (MD) simulations were conducted using the

- 361 1. LC McDonald, et al., Sars in healthcare facilities, toronto and taiwan. *Emerg. infectious*
362 *diseases* **10**, 777 (2004).
- 363 2. SY Cho, et al., Mers-cov outbreak following a single patient exposure in an emergency room
364 in south korea: an epidemiological outbreak study. *The Lancet* **388**, 994–1001 (2016).
- 365 3. LA Reperant, AD Osterhaus, Aids, avian flu, sars, mers, ebola, zika... what next? *Vaccine*
366 **35**, 4470–4474 (2017).
- 367 4. World health organization. coronavirus disease 2019 (covid-19)-situation report-146 (2020).
- 368 5. N Wang, J Shang, S Jiang, L Du, Subunit vaccines against emerging pathogenic human
369 coronaviruses. *Front. microbiology* **11**, 298 (2020).
- 370 6. J Cohen, Vaccine designers take first shots at covid-19 (2020).
- 371 7. TM Abd El-Aziz, JD Stockand, Recent progress and challenges in drug development against
372 covid-19 coronavirus (sars-cov-2)-an update on the status. *Infect. Genet. Evol.* **83**, 104327
373 (2020).
- 374 8. L Peeples, News feature: Avoiding pitfalls in the pursuit of a covid-19 vaccine. *Proc. Natl.*
375 *Acad. Sci.* **117**, 8218–8221 (2020).
- 376 9. N Vankadari, Arbidol: A potential antiviral drug for the treatment of sars-cov-2 by blocking the
377 trimerization of viral spike glycoprotein? *Int. J. Antimicrob. Agents*, 105998 (2020).
- 378 10. P Zhou, et al., A pneumonia outbreak associated with a new coronavirus of probable bat
379 origin. *nature* **579**, 270–273 (2020).
- 380 11. Y Wan, J Shang, R Graham, RS Baric, F Li, Receptor recognition by the novel coronavirus
381 from wuhan: an analysis based on decade-long structural studies of sars coronavirus. *J.*
382 *virology* **94**, 1–9 (2020).
- 383 12. Z Liu, et al., Composition and divergence of coronavirus spike proteins and host ace2
384 receptors predict potential intermediate hosts of sars-cov-2. *J. medical virology* **92**, 595–601
385 (2020).
- 386 13. D Wrapp, et al., Cryo-em structure of the 2019-ncov spike in the prefusion conformation.
387 *Science* **367**, 1260–1263 (2020).
- 388 14. AC Walls, et al., Structure, function, and antigenicity of the sars-cov-2 spike glycoprotein. *Cell*
389 **181**, 281–292 (2020).
- 390 15. R Yan, et al., Structural basis for the recognition of sars-cov-2 by full-length human ace2.
391 *Science* **367**, 1444–1448 (2020).
- 392 16. A Choudhury, S Mukherjee, In silico studies on the comparative characterization of the in-
393 teractions of sars-cov-2 spike glycoprotein with ace-2 receptor homologs and human tirs. *J.*
394 *medical virology*, 1–9 (2020).
- 395 17. Y Wang, M Liu, J Gao, Enhanced receptor binding of sars-cov-2 through networks of
396 hydrogen-bonding and hydrophobic interactions. *Proc. Natl. Acad. Sci.* **117**, 13967–13974
397 (2020).
- 398 18. M Amin, MK Sorour, A Kasry, Comparing the binding interactions in the receptor binding
399 domains of sars-cov-2 and sars-cov. *The J. Phys. Chem. Lett.* **11**, 4897–4900 (2020).
- 400 19. V Monteil, et al., Inhibition of sars-cov-2 infections in engineered human tissues using clinical-
401 grade soluble human ace2. *Cell* **181**, 905–913 (2020).
- 402 20. H Zhang, JM Penninger, Y Li, N Zhong, AS Slutsky, Angiotensin-converting enzyme 2 (ace2)
403 as a sars-cov-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive*
404 *care medicine* **46**, 586–590 (2020).
- 405 21. Y Han, P Král, Computational design of ace2-based peptide inhibitors of sars-cov-2. *ACS*
406 *nano* **14**, 5143–5147 (2020).
- 407 22. B Nami, A Ghanaeian, K Ghanaeian, N Nami, The effect of ace2 inhibitor mln-4760 on the
408 interaction of sars-cov-2 spike protein with human ace2: a molecular dynamics study. (2020).
- 409 23. R Shi, et al., A human neutralizing antibody targets the receptor binding site of sars-cov-2.
410 *Nature*, 1–8 (2020).
- 411 24. S Xia, et al., Inhibition of sars-cov-2 (previously 2019-ncov) infection by a highly potent pan-
412 coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate
413 membrane fusion. *Cell research* **30**, 343–355 (2020).
- 414 25. Y Wu, et al., A noncompeting pair of human neutralizing antibodies block covid-19 virus
415 binding to its receptor ace2. *Science* **368**, 1274–1278 (2020).
- 416 26. J Sun, Y Li, P Liu, J Lin, Study of the mechanism of protonated histidine-induced confor-
417 mational changes in the zika virus dimeric envelope protein using accelerated molecular dy-
418 namic simulations. *J. Mol. Graph. Model.* **74**, 203–214 (2017).
- 419 27. G Meher, S Sinha, GP Pattnaik, S Ghosh Dastidar, H Chakraborty, Cholesterol modulates
420 membrane properties and the interaction of gp41 fusion peptide to promote membrane fusion.
421 *The J. Phys. Chem. B* **123**, 7113–7122 (2019).
- 422 28. , *Lecithin*. (American Cancer Society), (2006).
- 423 29. E Nyankson, MJ DeCuir, RB Gupta, Soybean lecithin as a dispersant for crude oil spills. *ACS*
424 *Sustain. Chem. & Eng.* **3**, 920–931 (2015).
- 425 30. A Spinello, A Saltalamacchia, A Magistrato, Is the rigidity of sars-cov-2 spike receptor-binding
426 motif the hallmark for its enhanced infectivity? insights from all-atoms simulations. *The J.*
427 *Phys. Chem. Lett.* **11**, 4785–4790 (2020).
- 428 31. J Lan, et al., Structure of the sars-cov-2 spike receptor-binding domain bound to the ace2
429 receptor. *Nature* **581**, 1–6 (2020).
- 430 32. D Otzen, Protein–surfactant interactions: a tale of many states. *Biochimica et Biophys. Acta*
431 *(BBA)-Proteins Proteomics* **1814**, 562–591 (2011).
- 432 33. DM Small, M Bourges, D Derwichian, Ternary and quaternary aqueous systems containing
433 bile salt, lecithin and cholesterol. *Nature* **211**, 816–818 (1966).
- 434 34. M Abrams, Isolation and quantitative estimation of pulmonary surface-active lipoprotein. *J.*
435 *applied physiology* **21**, 718–720 (1966).
- 436 35. D Tierney, J Clements, H Trahan, Rates of replacement of lecithins and alveolar instability in
437 rat lungs. *Am. J. Physiol. Content* **213**, 671–676 (1967).
- 438 36. P van Hoogevest, Review—an update on the use of oral phospholipid excipients. *Eur. J.*
439 *Pharm. Sci.* **108**, 1–12 (2017).
- 440 37. RE Ostlund Jr, CA Spilburg, WF Stenson, Sitostanol administered in lecithin micelles potently
441 reduces cholesterol absorption in humans. *The Am. journal clinical nutrition* **70**, 826–831
442 (1999).
38. MJ Abraham, et al., Gromacs: High performance molecular simulations through multi-level
443 parallelism from laptops to supercomputers. *SoftwareX* **1**, 19–25 (2015).
39. E Lindahl, M Abraham, B Hess, D van der Spoel, the gromacs development team. *GROMACS*
444 *2020 Source code (Version 2020)*. Zenodo. (2020).
40. WL Jorgensen, DS Maxwell, J Tirado-Rives, Development and testing of the ops all-atom
445 force field on conformational energetics and properties of organic liquids. *J. Am. Chem. Soc.*
446 **118**, 11225–11236 (1996).
41. H Berendsen, J Grigera, T Straatsma, The missing term in effective pair potentials. *J. Phys.*
447 *Chem.* **91**, 6269–6271 (1987).
42. MC Bellissent-Funel, et al., Water determines the structure and dynamics of proteins. *Chem.*
448 *Rev.* **116**, 7673–7697 (2016).
43. BJ Berne, JD Weeks, R Zhou, Dewetting and Hydrophobic Interaction in Physical and Biolog-
449 ical Systems. *Annu. Rev. Phys. Chem.* **60**, 85–103 (2009).
44. D Chandler, Hydrophobicity: Two faces of water. *Nature* **417**, 491–491 (2002).
45. J Lan, et al., Structure of the sars-cov-2 spike receptor-binding domain bound to the ace2
450 receptor. *Nature* **581**, 215–220 (2020).
46. R Fleming, et al., Phospholipids for the treatment of infection by togaviruses, herpes viruses
451 and coronaviruses (2005) US Patent App. 10/783,927.
47. G Serrano, et al., Liposomal lactoferrin as potential preventative and cure for covid-19. *Int. J.*
452 *Res. Heal. Sci.* **8**, 8–15 (2020).
48. T Darden, D York, L Pedersen, Particle mesh ewald: An n log (n) method for ewald sums in
453 large systems. *The J. chemical physics* **98**, 10089–10092 (1993).
49. B Hess, H Bekker, HJ Berendsen, JG Fraaije, Lincs: a linear constraint solver for molecular
454 simulations. *J. computational chemistry* **18**, 1463–1472 (1997).
50. G Bussi, D Donadio, M Parrinello, Canonical sampling through velocity rescaling. *The J.*
455 *chemical physics* **126**, 014101 (2007).